Navigation Links
Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly
Date:11/13/2013

LONDON, November 13, 2013 /PRNewswire/ --

First-in-class antipsychotic therapy for Schizophrenia and Bipolar Disorders

Zysis, a private pharmaceutical company optimising therapies for disorders of the Central Nervous System, today announced that the United States Patent and Trademark Office has granted U.S. patent 8,575,172 covering its Phase II ready Long Acting Oral Aripiprazole Once Weekly (LAO Aripiprazole OW) product, a first-in-class antipsychotic therapy for orally dosed relapse prevention in patients suffering from Schizophrenia and Bipolar Disorders.

LAO Aripiprazole OW with medically supervised dosing is an alternative option to Long Acting Injectables (LAI) in the rapidly expanding market for prevention of psychotic relapse.  Non-adherence rates are extremely high with schizophrenia therapy; around 75% of patients are non-adherent within two years of being discharged from hospital[1], the consequences of which are medically and economically severe with 69% of patients with poor adherence suffering a relapse[2].

Peter Cozens, Chairman of Zysis said: "LAO Aripiprazole OW is a promising, cost effective option in the treatment of Schizophrenia, Schizoaffective Disorder and Bipolar Disorders for the large number of patients struggling with adherence.  We are very pleased to receive the U.S. Patent. This is an important event for Zysis. LAO Aripiprazole OW represents a breakthrough treatment providing another option to address unmet patient needs while improving their quality of life." 

Dr Robert Millet, Distinguished Fellow of the American Psychiatric Association and renowned US expert in long-acting therapies for the treatment of psychotic symptoms at Carolina Behavioral Care added: "I see adherence as a major factor in schizophrenia treatment today and this once weekly therapy has the potential to
'/>"/>

SOURCE Zysis
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
2. Dr. Rongxiang Xu Receives the Prestigious Scroll Award from Los Angeles County Government
3. Mainz University receives approval for an Alexander von Humboldt Professorship in Physics
4. Johns Hopkins Receives Prestigious ABET Accreditation for Its Part-time Master’s Degree in Systems Engineering
5. Ameritox Receives Accreditation from College of American Pathologists
6. Serial Entrepreneur, Rudy Mazzocchi, Receives Global Business Recognition Award as the 2013 Entrepreneur of the Year
7. Histogen’s Composition for Hair Growth Receives US Patent
8. Profound Medical Receives IDE Approval from FDA to Conduct TULSA Clinical Trial for New Treatment for Localized Prostate Cancer
9. Nasseo’s TiArray™ Dental Implant System Receives FDA Approval
10. Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
11. BioLineRxs BL-8040 Receives Orphan Drug Designation for Treatment of AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Empowering biomedical researchers with ... Cubresa Inc. today announced its MR Compatible Small ... PET Scanner uses silicon photomultiplier detector technology, so ... machines from manufacturers like Bruker and Agilent,” said ... Canada. “This enables simultaneous PET and MRI data ...
(Date:5/27/2015)... , May 27, 2015  US-Australian drug discovery and ... announced today that it will present at the Brain Tumor ... on May 29, 2015. The venue is the ... Manhattan . The Brain Tumor Biotech ... the pharmaceutical industry and the investment community to promote innovative ...
(Date:5/26/2015)... Miami (PRWEB) May 26, 2015 ... a new stem cells clinic in Buenos Aires, Argentina. ... a renowned critical care specialist. Pastrana has assembled a ... endocrinology and orthopedics in her state-of-the-art Puerto Madero office. ... operate phase I to phase IV clinical studies in ...
(Date:5/26/2015)... 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) ... CEO, will provide an update on the progress of Sangamo,s ... the company,s business strategy at 1:30pm ET on Monday, June ... conference is being held in New York, NY ... and may be accessed via a link on the Sangamo ...
Breaking Biology Technology:Cubresa Launches Simultaneous PET/MRI Technology 2Novogen to Present at Brain Tumor Biotech Summit 2015 2Novogen to Present at Brain Tumor Biotech Summit 2015 3Novogen to Present at Brain Tumor Biotech Summit 2015 4Novogen to Present at Brain Tumor Biotech Summit 2015 5Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... Tengion, Inc. (Nasdaq: TNGN ), a leader ... definitive agreements with certain investors in connection with a PIPE ... of 1933, as amended.  Medtronic (NYSE: MDT ), ... and, as part of its investment, secured a right of ...
... Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN ... eduction f or A dults R eceiving ... Overlake Hospital Medical Center in Bellevue and other major hospital ... determine a personalized warfarin dose for individual patients to reduce ...
... 28, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell processing, ... for the third quarter and first nine months of fiscal ... Quarter of Fiscal 2011 ...
Cached Biology Technology:Tengion Announces Pricing of $31.4 Million Private Placement 2Tengion Announces Pricing of $31.4 Million Private Placement 3WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 3China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 5China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 6China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 7China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 8China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 9China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 10China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 11
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... today announced that members of the executive management team will ... 43rd Annual Technology, Media and Telecom Conference Date: May ... in Boston, MA Cowen ... 2015 Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... December 17th, 2013 - Eurofins Medigenomix, a part of ... Orion Diagnostica Oy, an in vitro diagnostics company specialising ... systems, announced that they have signed a co-exclusive technology ... for the SIBA isothermal nucleic acid detection technology in ...
... birth to live young, rather than laid eggs, and over ... reproductive mode, according to research published in print in ... unusual and controversial finding, and a major overturn of an ... Assistant Professor of Biology in the Columbian College of Arts ...
... controlling the temperature of silica rods as they grow, ... Laboratory could be setting the stage for advances in ... and more. The goal of fabricating fixed-size one-dimensional ... diameter during growth has long eluded scientists. Now, Panos ...
Cached Biology News:Ancestor of snakes, lizards likely gave birth to live young 2ORNL devises recipe to fine-tune diameter of silica rods 2
Request Info...
...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: